May 8, 2012
Eleven Biotherapeutics Secures $20 Million and Expands Series A Financing » Press Release | Company News
May 8, 2012
Oncology Expert George Demetri, M.D., Joins Blueprint Medicines as a Clinical Advisor » Press Release | Company News
our investments
"Third Rock makes significant investments in innovative science. For our company, that has been transformational. For the rare genetic disorder of dystrophic epidermolysis bullosa (DEB), this commitment has literally galvanized an entire patient community. An area that has been underserved is now in the spotlight and we have the opportunity to change patients' lives. Third Rock's commitment has become a symbol of hope for an entire population of patients and families devastated by DEB."
Mark P. de Souza, Ph.D. President and CEO of Lotus Tissue Repair
With every partnership, we invest our time, talent, leadership, operational expertise and R&D insight that you can’t get in a short monthly board meeting. We are company builders and focus on hands-on collaboration to identify disruptive science and technology that will shape the future of medicine. Our investments include companies formed around cutting edge approaches to epigenetics, cancer metabolism, obesity, rare genetic disorders, pain and molecular diagnostics.
When we get involved in the formative stages of company, we consider investments based on the following criteria:
We invest for success…
Our strategy is to lead investing rounds in uniquely innovative life sciences businesses, making an initial investment of up to $35 million, ideally at the formative stage of company development.
…with extraordinary scientists and entrepreneurs…
We seek to work with great founders who possess inspiration, insight and tenacity.
…who have transformational ideas…
We seek opportunities to build companies around breakthrough innovations and “product engines” - new platforms capable of creating multiple products for different diseases. We engage early in our investment process with large life sciences companies, exploring novel, mutually beneficial partnerships to launch successful biotech and medtech companies together.
… to which we can add value.
We pursue opportunities where we can add value through our unique collaborative approach to launch companies, and provide scientific or business expertise as well as capital to help accelerate their growth.
